Candesartan is one of the first angiotensin II receptor antagonists (AIIRAs) to be developed. It binds tightly to and dissociates slowly from the angiotensin subtype 1 (AT 1 ) receptor in vitro. These binding characteristics differ from those of losartan, which demonstrates lower affinity and faster dissociation from the AT 1 receptor. Candesartan causes long-lasting antagonism of the vascular contractile response to angiotensin II compared with irbesartan, losartan or the active metabolite of losartan -EXP-3174. While there are relatively few distinc-
Introduction
Angiotensin II receptor antagonists (AIIRAs) represent an important new class of antihypertensive agents which enable a more specific and complete block of the renin-angiotensin system (RAS) compared with angiotensin-converting enzyme (ACE) inhibitors. The AIIRAs selectively block the angiotensin subtype 1 receptor (AT 1 ), which mediates most of the known actions of angiotensin II.
The development of AIIRAs has overcome some of the difficulties apparent with ACE inhibition. Regardless of whether the angiotensin II is produced by ACE or ACE-independent pathways, such as tissue chymase, chymostatin-sensitive angiotensin II-generating enzyme (CAGE), cathepsin G and others, 1,2 the AIIRAs cause a highly specific block of the angiotensin II at its receptor. Although ACE inhibitors are efficacious and have relatively few side effects, 3 the lack of specificity of ACE inhibition results in a potentiation of endogenous kinins (bradykinin and tachykinin) associated with classspecific side effects such as angioedema and dry cough. 4 In the early 1980s, Takeda Chemical Industries, Ltd 5 described the first non-peptide derivatives angiotensin antagonists (CV-2198, CV-2973 and CV-2961), which were considered specific but weak antagonists at the AT 1 receptor. These molecules served as structural templates for the development of a series of new compounds that were selected on the basis of their improved oral bioavailability and potency at the AT 1 receptor (Figure 1) . 6 Since the introduction of the prototype losartan in 1994, new agents such as candesartan cilexetil, valsartan, irbesartan, telmisartan and eprosartan have been made available. These agents have been shown to combine blood pressure-lowering efficacy -comparable with ACE inhibitors and calcium channel blockers -with a tolerability profile comparable with placebo. In addition to, and perhaps independent of, their antihypertensive action, their potent inhibition of the RAS is expected to bring additional benefits for the management of heart failure and renal disease (associated with diabetes mellitus).
When used once daily, either as monotherapy or in combination with other antihypertensive agents, the AIIRAs are effective for the management of patients with mild, moderate and severe hypertension. As well-tolerated antihypertensive agents, the AIIRAs are important new tools for the primary prevention of cardiovascular morbidity and mortality.
This paper reviews new data, comparing the pharmacodynamics and clinical efficacy of candesartan cilexetil with the other members of this new class. While all of these drugs are highly selective for the AT 1 receptor, there are important differences in their pharmacology, pharmacokinetics and pharmacodynamics that are reflected in their duration of antihypertensive effect. In particular, they differ in affinity constants, especially dissociation constants from the receptor, antagonism characteristics and in vivo pharmacodynamics. 
Differential preclinical pharmacology of AIIRAs

Receptor binding affinity and specificity
Like all the AIIRAs in clinical development, candesartan is a potent and selective AT 1 receptor blocker. Candesartan dose-dependently inhibited the in vitro binding of radiolabelled angiotensin II at the AT 1 receptor in rabbit aorta but did not interact with the angiotensin subtype 2 (AT 2 ) receptor in the bovine cerebellum. Candesartan had a Ͼ10 000-fold higher affinity for the AT 1 receptor compared with the AT 2 receptor. 7 The affinity of candesartan for the AT 1 receptor was 80 times greater than that of losartan and 10 times greater than the active metabolite of losartan, EXP-3174. 7 In human resistance vessels, candesartan is 1000 times as potent as losartan. 8 The comparative potency of the AIIRAs was further evaluated in human AT 1 receptors, isolated from a human heart cDNA library and transfected into COS-7 cells. 9 The inhibitory effects of EXP-3174, eprosartan, irbesartan, candesartan and valsartan on [I 125 ] angiotensin II receptor binding were compared. The results (Table 1) showed that candes- artan was the most potent of the AIIRAs tested; potencies were candesartan у irbesartan Ͼ EXP-3174 Ͼ eprosartan and valsartan.
Antagonistic properties
The angiotensin II-mediated vascular contractile responses in isolated rat portal vein and rabbit aorta in the presence of AIIRAs have been investigated independently by a number of research groups. [10] [11] [12] [13] [14] [15] These studies have found that while candesartan (0.01-1 nM) produces a clear dose-dependent reduction in the maximal contractile response to angiotensin II (characteristic of insurmountable or non-competitive antagonism), 15 losartan and eprosartan are displaced from the AT 1 receptor with increasing doses of angiotensin II and cause parallel shifts of the dose response without affecting the maximal effect of angiotensin II (competitive or surmountable antagonism). 10, 11, 14 Valsartan, irbesartan and EXP-3174 (the active metabolite of losartan) exhibit mixed-type competitive (or surmountable) and non-competitive (insurmountable) antagonism at the AT 1 receptor; 11, 12 telmisartan exhibits insurmountable (non-competitive) but reversible inhibition to angiotensin II-induced contractions in isolated rabbit aortic tissue. 13 The antagonistic properties of candesartan, irbesartan, losartan and its active metabolite EXP-3174 were compared by Morsing and colleagues ( Figure  2) . 16 The investigations were conducted in isolated preparations of rat portal vein and rabbit thoracic aortic strips using concentrations of antagonists equivalent to the (non-protein-bound) plasma concentrations achieved with oral dosing. The study found similar concentration curves in both rabbit aorta and rat portal vein, which have different tissue reserves of AT 1 receptor. In rabbit aorta, increasing doses of angiotensin II displaced irbesartan (1-100 nM), losartan (1-100 nM) and its metabolite EXP-3174 (0.1-10 nM) from the AT 1 receptor, resulting in parallel shifts in the contractile responses to angiotensin II. Candesartan (0.03-1 nM) reduced the maximum response to angiotensin II, causing a characteristic non-parallel shift in the dose-response curve of angiotensin II. At 1 nM candesartan, the angiotensin II response was completely suppressed. For irbesartan (100 nM), some degree of suppression of the angiotensin II response was also recorded at the highest concentrations in rabbit aortic strips.
It is likely that the mixed insurmountable and surmountable antagonism observed under different
Journal of Human Hypertension experimental conditions with drugs such as irbesartan may reflect the rate of dissociation from the AT 1 receptor. When experiments with irbesartan were repeated in isolated rabbit aortic strips after equilibrium had been reached at 22 h after washout, irbesartan was shown to have competitive antagonism.
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Kinetics at the AT 1 receptor
Candesartan binds tightly to and dissociates slowly from the AT 1 receptor in vitro. 17 These binding characteristics differ from those of losartan, which demonstrates lower affinity and faster dissociation from the AT 1 receptor.
17,18
The duration of binding has been assessed in a direct comparison of losartan, EXP-3174, irbesartan and candesartan in an isolated rat portal vein preparation. 19 The AIIRAs were introduced for a period of 1 h, after which the drugs were washed out. This study showed that while the inhibitory effect of candesartan persisted, the responses to angiotensin II rapidly returned to baseline values with irbesartan, losartan or EXP-3174 after washout (Figure 3 ). 19 Compared with irbesartan, losartan or EXP-3174, candesartan causes long-lasting antagonism of the vascular contractile response to angiotensin II. 19 
Differential pharmacodynamics
AIIRAs block the blood pressure response to exogenous angiotensin II in healthy volunteers, decrease baseline blood pressure in both normal and hypertensive patients, produce a marked rise in plasma renin activity and endogenous angiotensin II and increase renal blood flow without altering glomerular filtration rate. These effects are dose dependent, but their time course varies between the drugs owing to pharmacokinetic and pharmacodynamic differences.
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Antagonism of the pressor response
The ability of candesartan cilexetil to antagonise angiotensin II was compared with losartan in healthy volunteers 21 in a double-blind cross-over study. Twelve healthy volunteers received either candesartan cilexetil 8 mg or losartan 50 mg followed 48 h later by daily doses for 6 days. Angiotensin II was infused at 3-min intervals at ascending doses from 0.17 to 20g/min or until diastolic blood pressure (DBP) had increased by 25 mm Hg. Angiotensin II antagonism was determined by recording DBP at the end of each angiotensin II infusion step and constructing individual dose-response curves using an E max model. Both candesartan cilexetil and losartan reached peak concentrations after 4 -5 h and were still detectable after 24 h. Concentration equivalents at times у24 h were greater for candesartan cilexetil, with the maximum effect of candesartan cilexetil being 1.65 and 1.94 times that of losartan after single and repeated administration, respectively. 21 The antagonistic effect of candesartan increased by 1.33 from day 1 to day 8, while no increase was observed for losartan. Thus, compared with losartan, candesartan cilexetil had an antagonistic effect on angiotensin II that was markedly greater and longer lasting. 21 This effect may be explained by its tighter binding and slower dissociation from the AT 1 receptor compared with losartan. 22 The antagonistic potency of candesartan cilexetil (4 mg, 8 mg and 16 mg) has also been compared with irbesartan (75 mg, 150 mg, 300 mg), losartan (25 mg, 50 mg, 100 mg) and valsartan (40 mg, 80 mg, 160 mg) in humans. 23 The dose-response curves of exogenous angiotensin II on DBP were evaluated at regular time points up to 24 h after oral dosing with the AT 1 -receptor blockers. At each time point, the K i or dose required to shift the dose-response curve two-fold to the right was calculated. The results showed that the K i doses 24 h after oral administration were 6 mg for candesartan, 123 mg for irbesartan and 93.5 mg for valsartan; however, a K i value for losartan could not be determined because of its very small effect at this time point. 23 These results confirm the findings from in vitro and in vivo studies that candesartan has the highest direct angiotensin II antagonistic activity per mg at 24 h after dosing.
Renin stimulation
The efficacy of AT 1 -receptor antagonists is not only influenced by pharmacological and pharmacodynamic properties of the drug but also by patientdependent factors: the more active the RAS, the stronger the antihypertensive response. In a human model in which mild sodium depletion in normotensive subjects was used to control renin status, the pharmacodynamic effects (fall in blood pressure and increase in active renin) of single oral doses of candesartan cilexetil (8 mg, 16 mg) and losartan (50 mg) were evaluated. 24 This double-blind placebo-controlled study involved 16 healthy subjects pretreated with a single dose of furosemide 40 mg. Mean blood pressure levels, plasma active renin, angiotensin I and angiotensin II levels were determined and correlated with the plasma candesartan and EXP-3174 levels over 24 h. The study found large inter-subject variability in the plasma pharmacokinetics of EXP-3174 whereas the inter-subject variability for patients on candesartan was low. This was reflected in the greater inter-subject variability of plasma active renin levels with losartan compared with candesartan. Another primary endpoint evaluated in this study was the duration of response of AIIRAs. At 24 h, the inhibition of the RAS (as measured by AUC 0-24h active renin levels) was sig- Further evaluation using the same experimental design found that candesartan cilexetil 16 mg achieved a more prolonged and more potent blockade of the RAS than valsartan 160 mg or 80 mg (P Ͻ 0.05) ( Table 2) . 25 The intra-individual active renin stimulation was found to be highly reproducible and the ratio of the drug AUC 0-9h :active renin AUC 0-9h was almost constant for both candesartan cilexetil and valsartan at each dose and was correlated between drugs.
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While the pharmacodynamics of candesartan cilexetil clearly differentiate it from the other AIIRAs, pharmacokinetic parameters show few differences (Table 3) . [26] [27] [28] [29] [30] [31] [32] [33] A better correlation for the prolonged and potent inhibition of the RAS by candesartan may be its high affinity and slow dissociation from the AT 1 receptor.
Clinical experience
In the clinic, candesartan cilexetil is administered once daily and is completely and rapidly hydrolysed during gastrointestinal absorption to candesartan, the active moiety.
14 Once-daily candesartan cilexetil lowers the ambulatory blood pressure over 24 h without affecting circadian variations in blood pressure. 34 This reduction in arterial pressure is accompanied by a reduction in total peripheral resistance and renovascular resistance and an increase in renal blood flow. 35 In a meta-analysis of studies involving 1482 patients with mild-to-moderate hypertension, can- Journal of Human Hypertension desartan cilexetil (4 -16 mg) produced a dose-dependent reduction in both DBP and systolic blood pressure (SBP). 36 On average, the placebo-corrected changes in sitting DBP from baseline were 4.5, 6 and 8 mm Hg with candesartan 4 mg, 8 mg and 16 mg, respectively, 24 h after dosing. The placebo-corrected blood pressure reductions were not affected by age, gender or baseline blood pressure. 36 Other AIIRAs, valsartan, irbesartan and telmisartan, have also shown dose-response curves [37] [38] [39] but losartan, by contrast, displays a flat dose-response. 40 
Comparative clinical efficacy
The efficacy of candesartan cilexetil 8 mg once daily was compared with losartan 50 mg once daily over 36 h using ambulatory blood pressure monitoring in the clinic before and after 6 weeks of double-blind treatment. 41 In total, 256 patients with mild-to-moderate (Ͻ95/115 mm Hg) essential hypertension were evaluated in an intention-to-treat analysis. The primary endpoints were the changes in mean blood pressure from baseline after 6 weeks of study treatment; blood pressure measurements were made at 0-24 h and 0-36 h after the last dose and during the day (07.00-22.00) and night (22.00-07.00). Compared with losartan 50 mg, the mean ambulatory DBP changes from baseline were greater with candesartan cilexetil 8 mg at both 0-24 h (P Ͻ 0.05) and 24 -36 h (P Ͻ 0.01) after dosing. Furthermore, the magnitude of the ambulatory blood pressure response was also significantly greater with candesartan cilexetil (16 mg) compared with losartan 50 mg for both day (P = 0.018) and night (P = 0.011) measurements, indicating significantly better peak and trough values for candesartan cilexetil. These results were confirmed by Andersson and Neldham 41 who found that the placebo-corrected trough:-peak ratio for candesartan approached 1.0 (0.9-1.1) compared with 0.7 for losartan, demonstrating improved 24-h blood pressure control with candesartan compared with losartan in patients with mildto-moderate hypertension.
In another placebo-controlled randomised study, the higher dose of losartan (100 mg) was compared with candesartan cilexetil 16 mg over 8 weeks in 268 patients with mild-to-moderate hypertension. 42 The study found that the differences in average changes in ambulatory blood pressure (from baseline) over 36 h were significantly greater with candesartan cilexetil 16 mg compared with losartan 100 mg, the differences between the drugs averaging 5.8 mm Hg (SBP) and 3.5 mm Hg (DBP) (Figure 4 ). 42 These differences became even more marked at 48 h after dosing, when the effect of candesartan cilexetil was maintained but there was little or no remaining effect of losartan. This study showed that the improved long-lasting efficacy of candesartan compared with losartan becomes even more apparent for measurements beyond the 24-h dosing interval.
No direct comparative studies of candesartan cilexetil with the other AIIRAs have been conducted to date. However, provisional evidence of mean placebo-corrected reductions in DBP from two studies, one comparing losartan with irbesartan 43 and the other comparing losartan with candesartan cilexetil, 44 indicate that both the new AIIRAs are superior to losartan (P Ͻ 0.01 for both) and exert a comparable reduction in DBP (−8.0 mm Hg with candesartan cilexetil; −6.8 mm Hg with irbesartan) ( Figure  5 ). 
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Clinical efficacy vs usual treatment
Recent studies have also demonstrated comparable efficacy of candesartan cilexetil with other antihypertensive drugs such as the calcium antagonist amlodipine. 46 Comparable efficacy with the ACE inhibitor enalapril has been demonstrated for all the new AIIRAs including candesartan cilexetil, [47] [48] [49] [50] irbesartan, 51 valsartan 52 and telmisartan. 53 In three double-blind randomised studies of patients with mild-to-moderate hypertension (sitting DBP 95-114 mm Hg), candesartan cilexetil exerted a reduction in blood pressure comparable with enalapril but with a better side-effect profile. [47] [48] [49] In a recent placebo-controlled, randomised study by Malmqvist et al 50 in 429 middle-aged hypertensive women, candesartan cilexetil (8-16 mg) lowered both SBP and DBP more effectively than either enalapril (10-20 mg) or hydrochlorothiazide (HCTZ) (12.5-25 mg) after 6 and 12 weeks of treatment. The difference in magnitude of response with candesar-S39 tan was significant compared with both enalapril (−19 mm Hg for candesartan cilexetil vs −13.5 mm Hg for enalapril; P = 0.003) and HCTZ (−19 mm Hg for candesartan vs −12.9 mm Hg for HCTZ; P Ͻ 0.001). Furthermore, the study found that patients taking enalapril experienced significantly more discomfort from dry cough than those taking candesartan cilexetil or HCTZ. These findings were confirmed in a study by Tanser et al 54 who found that, in patients who experienced dry cough with enalapril, a switch to either candesartan cilexetil or placebo resulted in equal relief from this adverse event.
Tolerability profile
The tolerability of candesartan cilexetil has been shown to be similar to that of placebo in an analysis of more than 3000 patients and volunteers who received the drug at doses of up to 16 mg/day in Phase I-III trials. 55 Total exposure to the drug was 854 patient-years.
In double-blind clinical trials, patients with mildto-moderate hypertension treated with candesartan cilexetil experienced an incidence of adverse events that was comparable with that of placebo. Candesartan cilexetil was equally well tolerated by women and men and by the young, elderly (у65 years) and very elderly (у75 years), 56 the latter being a population that is often beset with a variety of tolerability problems.
Candesartan cilexetil had no adverse metabolic effects and was well tolerated in the long term (up to 1 year). Orthostatic or first-dose hypotensive effects and rebound hypertension after cessation of therapy were not associated with candesartan cilexetil. Importantly, the incidence of cough was the same as with placebo (1.6 % for candesartan cilexetil; 1.1% for placebo) and candesartan cilexetil had no apparent effect on plasma potassium concentrations. 55 Consistent with its metabolic inactivity, candesartan had no effect on glucose homeostasis or serum lipids when given to patients with hypertension and type II diabetes for 12 weeks.
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Conclusions
Candesartan cilexetil represents a new generation of once-daily oral antihypertensive agents that cause a specific block of the RAS. Candesartan cilexetil binds tightly to and dissociates slowly from the AT 1 receptor. These binding characteristics differ from those of losartan, which demonstrates lower affinity and faster dissociation from the AT 1 receptor. Candesartan causes long-lasting antagonism of the vascular contractile response to angiotensin II compared with irbesartan, losartan or the active metabolite of losartan -EXP-3174. In humans, candesartan cilexetil produces a more complete and prolonged blockade of the RAS than losartan 50 mg. While there are relatively few distinctions that can be made between the AIIRAs in terms of their pharmacokinetic profiles, the antagonistic potency of candesartan cilexetil at the AT 1 receptor over 24 h clearly differentiates it from other members of this Journal of Human Hypertension class. These differences are reflected in the antihypertensive efficacy and duration of action of candesartan in clinical trials.
A number of clinical trials have shown that over the therapeutic dose range studied, candesartan cilexetil 4 -16 mg produces linear and dose-dependent reductions in both SBP and DBP that are unaffected by factors such as age or gender. The magnitude of the blood pressure-lowering effect with candesartan is at least equivalent to several other widely used antihypertensive agents, and is perhaps more effective than losartan. Comparison of the mean placebo-corrected reduction in DBP across trials would seem to indicate the superior efficacy of both irbesartan and candesartan relative to losartan. This has been confirmed in a direct comparative study of once-daily candesartan cilexetil 8 mg and 16 mg and losartan 50 mg, and more recently in a comparison of candesartan cilexetil 16 mg and losartan 100 mg. Candesartan cilexetil 16 mg had a clinically significantly greater blood pressure-lowering effect than losartan 50 mg after 24 h (P = 0.013).
Measures beyond 24 h after dosing show even greater differences between the efficacies of candesartan and losartan. Mean changes in ambulatory SBP and DBP (from baseline) over 36 and 48 h were significantly greater (P Ͻ 0.01) with candesartan cilexetil 16 mg than with losartan 100 mg. The clinically superior efficacy of candesartan in maintaining its antihypertensive action over 24 h and up to 48 h may provide an added benefit if patients miss a dose of treatment.
In conclusion, the emerging clinical profile of candesartan cilexetil provides evidence for its potent and long-lasting blood pressure-lowering effect. The ability of candesartan cilexetil to effectively lower blood pressure throughout the 24-h dose interval is consistent with its distinct receptor binding characteristics within the AIIRAs, and its pharmacokinetic and pharmacodynamic characteristics confer flexibility in terms of its dosage administration.
